Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
| DWPI Title: Cell-targeting porous protocell useful for treating cancer, comprises nanoporous silica or metal oxide core with supported lipid bilayer and further component e.g. cell targeting species, fusogenic peptide, plasmid DNA and drug |
| Use: For treating cancer, such as hepatocellular cancer, squamous-cell carcinoma, adenocarcinoma, hepatocellular carcinoma, renal cell carcinomas, carcinoma of the bladder, bone, bowel, breast, cervix, colon (colorectal), esophagus, head, kidney, liver (hepatocellular), lung, nasopharyngeal, neck, ovary, testicles, pancreas, prostate, and stomach; leukemia, Burkitt's lymphoma, Non-Hodgkin's lymphoma, B-cell lymphoma; malignant melanoma; myeloproliferative diseases; Ewing's sarcoma, hemangio sarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma,synovial sarcoma; gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, Schwannomas, bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, non-small cell lung cancer, small cell lung cancer, mixed small cell and non-small cell lung cancer, pleural mesothelioma, pleural mesothelioma, testicular cancer, thyroid cancer and astrocytoma (claimed). |
| Advantage: The protocell improves the activity of chemotherapeutic agents and to enhance cancer therapy is ongoing; and improves the delivery of agents which can influence therapeutic outcome, whether by enhancing the administration of cancer therapeutic agents or in diagnostics, to facilitate approaches to diagnosing cancer and monitoring cancer therapy. |
| Novelty: A cell-targeting porous protocell (P1) comprises: a nanoporous silica or metal oxide core with a supported lipid bilayer and at least one further component selected from a cell targeting species; a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA, and other cargo comprising at least one cargo component selected from double stranded linear DNA; plasmid DNA; a drug; an imaging agent, small interfering RNA, small hairpin RNA and/or microRNA, where one of the cargo components is optionally conjugated further with a nuclear localization sequence. |
| Filed: 12/4/2013 |
| Application Number: US14113371A |
| Tech ID: SD 12442.2 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |